Tekla Healthcare Investors: management transactions · United States · SEC (Form 4)

About Tekla Healthcare Investors

Tekla Healthcare Investors is a U.S.-listed closed-end investment company historically traded on the NYSE under the ticker HQH and now managed within the abrdn Healthcare Investors platform after the adviser change that took effect on October 27, 2023. For investors looking at the name from a capital-markets perspective, it is important to note that this is not an operating healthcare company but a non-diversified Massachusetts business trust formed on October 31, 1986 and launched on April 22, 1987. Its stated objective is long-term capital appreciation through investments in equity and related securities of U.S. and foreign companies principally engaged in the healthcare industries. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000805267/000110465925119339/tm2527059d11_ncsr.htm?utm_source=openai)) The fund’s business profile is therefore best understood as a specialized listed healthcare allocation vehicle. Rather than manufacturing drugs, providing clinical services, or selling medical devices directly, Tekla Healthcare Investors gains exposure to the healthcare value chain through a portfolio of publicly traded securities. In practical terms, that means the portfolio can include biotechnology, pharmaceuticals, medical technology, healthcare services, and other healthcare-related businesses, depending on the manager’s positioning. This makes HQH a thematic investment wrapper for investors seeking sector exposure to healthcare innovation, aging demographics, and life-sciences growth in the United States and abroad. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000805267/000110465925119339/tm2527059d11_ncsr.htm?utm_source=openai)) From a competitive standpoint, the fund’s differentiators are its long history, specialist mandate, and established investor base in the U.S. listed closed-end fund universe. Its structure is particularly relevant for income- and total-return-oriented investors who want public-market healthcare exposure with daily trading liquidity on a major U.S. exchange. SEC filings show a Boston, Massachusetts address at 100 Federal Street, 19th Floor, Boston, MA 02110, reinforcing its U.S. domicile and operational footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/805267/000110465922037466/0001104659-22-037466-index.htm?utm_source=openai)) Recent milestones have centered on governance and management rather than operating transformation. The most important recent event was the transfer of management from Tekla Capital Management LLC to abrdn Inc. effective October 27, 2023, together with the rebranding of the fund to abrdn Healthcare Investors. The transition preserved the healthcare-focused investment mandate while changing the adviser and board composition. More recently, SEC reporting has continued to frame the fund’s performance around healthcare market conditions, including biotech and regulatory catalysts. For French-speaking investors, the key takeaway is that Tekla Healthcare Investors remains a U.S. healthcare-sector listed exposure vehicle tied to the United States market and the NYSE legacy listing, with a portfolio-driven business model rather than an operating-company model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/805267/000110465925119339/tm2527059d11_ncsr.htm?utm_source=openai))